András Harsányi

444 total citations
15 papers, 181 citations indexed

About

András Harsányi is a scholar working on Economics and Econometrics, Immunology and Clinical Psychology. According to data from OpenAlex, András Harsányi has authored 15 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 4 papers in Immunology and 3 papers in Clinical Psychology. Recurrent topics in András Harsányi's work include Pharmaceutical Economics and Policy (10 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Biosimilars and Bioanalytical Methods (4 papers). András Harsányi is often cited by papers focused on Pharmaceutical Economics and Policy (10 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Biosimilars and Bioanalytical Methods (4 papers). András Harsányi collaborates with scholars based in Hungary, Romania and Bulgaria. András Harsányi's co-authors include Marcell Csanádi, Paweł Kawalec, Tomáš Tesař, Zoltán Kaló, Guenka Petrova, Ewa Stawowczyk, Adina Turcu-Ştiolică, András Inotai, Attila Németh and Attila Németh and has published in prestigious journals such as International Journal of Molecular Sciences, Frontiers in Pharmacology and Value in Health.

In The Last Decade

András Harsányi

14 papers receiving 177 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
András Harsányi Hungary	8	102	54	27	27	18	15	181
Mark Ratcliffe United Kingdom	7	108 1.1×	36 0.7×	30 1.1×	48 1.8×	162 9.0×	9	324
Teresa O'Sullivan United Kingdom	5	33 0.3×	218 4.0×	28 1.0×	19 0.7×	34 1.9×	6	303
Vivien Kin Yi Chan Hong Kong	9	34 0.3×	6 0.1×	9 0.3×	26 1.0×	12 0.7×	19	256
P Robert United States	3	39 0.4×	436 8.1×	15 0.6×	37 1.4×	106 5.9×	3	541
The Lancet Neurology	6	9 0.1×	11 0.2×	4 0.1×	18 0.7×	12 0.7×	20	159
Dragan Mitrović Serbia	8	6 0.1×	14 0.3×	4 0.1×	32 1.2×	15 0.8×	32	184
Dimittri Delevry United States	9	8 0.1×	21 0.4×	3 0.1×	14 0.5×	3 0.2×	22	269
Stephanie Gallant United Kingdom	9	11 0.1×	7 0.1×	8 0.3×	13 0.5×	5 0.3×	13	202
Ansgar Weyergraf Germany	6	10 0.1×	135 2.5×	4 0.1×	7 0.3×	21 1.2×	10	176
Claire Brock United Kingdom	6	10 0.1×	16 0.3×	47 1.7×	14 0.5×	8 0.4×	24	209

Countries citing papers authored by András Harsányi

Since Specialization

Citations

This map shows the geographic impact of András Harsányi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by András Harsányi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites András Harsányi more than expected).

Fields of papers citing papers by András Harsányi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by András Harsányi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by András Harsányi. The network helps show where András Harsányi may publish in the future.

Co-authorship network of co-authors of András Harsányi

This figure shows the co-authorship network connecting the top 25 collaborators of András Harsányi. A scholar is included among the top collaborators of András Harsányi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with András Harsányi. András Harsányi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Harsányi, András, Ágnes Molnár, Hajnalka Lőrincz, et al.. (2025). Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study. International Journal of Molecular Sciences. 26(13). 5951–5951.

Vončina, Luka, Jurij Fürst, Maria Dimitrova, et al.. (2021). Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. Applied Health Economics and Health Policy. 19(6). 915–927. 6 indexed citations

Harsányi, András, et al.. (2019). Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Review of Pharmacoeconomics & Outcomes Research. 20(6). 653–659. 6 indexed citations

Harsányi, András, et al.. (2019). PBI24 UTILIZATION AND SWITCHING PATTERNS OF BIOLOGICAL MEDICINES IN THE INDICATIONS OF INFLIXIMAB BEFORE AND AFTER PATIENT EXPIRY. Value in Health. 22. S51–S51. 1 indexed citations

Harsányi, András, et al.. (2018). Biosimilar Infliximab Utilization After Patent Expiry: The Case of Colitis Ulcerosa and Rheumatoid Arthritis in Hungary. Value in Health. 21. S95–S96. 1 indexed citations

Csanádi, Marcell, Olga Löblová, Piotr Ozierański, et al.. (2018). When health technology assessment is confidential and experts have no power: the case of Hungary. Health Economics Policy and Law. 14(2). 162–181. 19 indexed citations

Kamusheva, Maria, Manoela Manova, Guenka Petrova, et al.. (2018). Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Frontiers in Pharmacology. 9. 795–795. 15 indexed citations

Kawalec, Paweł, Tomáš Tesař, Manoela Manova, et al.. (2017). Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Frontiers in Pharmacology. 8. 892–892. 33 indexed citations

Elek, Péter, et al.. (2017). Policy objective of generic medicines from the investment perspective: The case of clopidogrel. Health Policy. 121(5). 558–565. 9 indexed citations

10.

Inotai, András, Marcell Csanádi, András Harsányi, & Bertalan Németh. (2017). Drug Policy in Hungary. Value in Health Regional Issues. 13. 16–22. 12 indexed citations

11.

Kawalec, Paweł, Ewa Stawowczyk, Tomáš Tesař, et al.. (2017). Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Frontiers in Pharmacology. 8. 288–288. 43 indexed citations

12.

Harsányi, András, et al.. (2012). The validation of the Hungarian version of the dimensional Yale-Brown obsessive-compulsive scale.. PubMed. 65(1-2). 25–33. 2 indexed citations

13.

Racsmány, Mihály, et al.. (2010). An experimental study of prospective memory in obsessive-compulsive disorder. Journal of Clinical and Experimental Neuropsychology. 33(1). 85–91. 16 indexed citations

14.

Harsányi, András, et al.. (2009). [Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test].. PubMed. 24(1). 18–59. 3 indexed citations

15.

Harsányi, András, et al.. (2007). [New approach to obsessive-compulsive disorder: dopaminergic theories].. PubMed. 22(4). 248–58. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact